Perspective Therapeutics (CATX) 10-Q 10 May 16 2016 Q3 Quarterly report Financial data

Document And Entity Information

Document And Entity Information - shares	9 Months Ended
	Mar. 31, 2016	May. 06, 2016
Document Information [Line Items]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Mar. 31, 2016
Document Fiscal Year Focus	2,016
Document Fiscal Period Focus	Q3
Entity Registrant Name	IsoRay, Inc.
Entity Central Index Key	728,387
Current Fiscal Year End Date	--06-30
Entity Filer Category	Accelerated Filer
Trading Symbol	ISR
Entity Common Stock, Shares Outstanding		55,010,619

Consolidated Balance Sheets

Consolidated Balance Sheets - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Current assets:
Cash and cash equivalents	$ 5,694,339	$ 5,226,740
Certificates of deposit	5,910,756	9,362,574
Accounts receivable, net of allowance for doubtful accounts of $30,000 and $30,000, respectively	883,702	1,049,041
Inventory	457,291	403,955
Other receivables	5,098	19,615
Prepaid expenses and other current assets	288,977	263,597
Total current assets	13,240,163	16,325,522
Property and equipment, net	415,675	574,840
Certificates of deposit, non-current	5,191,960	5,106,775
Restricted cash	181,368	181,262
Inventory, non-current	544,363	569,854
Other assets, net of accumulated amortization	222,529	245,031
Total assets	19,796,058	23,003,284
Current liabilities:
Accounts payable and accrued liabilities	732,018	498,253
Accrued protocol expense	97,679	124,131
Accrued radioactive waste disposal	164,544	129,500
Accrued payroll and related taxes	119,165	212,795
Accrued vacation	98,874	127,515
Total current liabilities	1,212,280	1,092,194
Long-term liabilities:
Warrant derivative liability	45,000	181,000
Asset retirement obligation	1,013,782	947,849
Total liabilities	$ 2,271,062	$ 2,221,043
Commitments and contingencies
Shareholders' equity:
Common stock, $.001 par value; 192,998,329 shares authorized; 55,010,619 and 54,967,559 shares issued and outstanding	$ 55,010	$ 54,968
Treasury stock, at cost, 0 and 13,200 shares, respectively	0	(8,390)
Additional paid-in capital	82,727,429	82,467,111
Accumulated deficit	(65,257,502)	(61,731,507)
Total shareholders' equity	17,524,996	20,782,241
Total liabilities and shareholders' equity	19,796,058	23,003,284
Series A Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	0	0
Series B Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	59	59
Series C Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	0	0
Series D Preferred Stock [Member]
Shareholders' equity:
Preferred Stock, Value, Issued	$ 0	$ 0

Consolidated Balance Sheets (Pa

Consolidated Balance Sheets (Parenthetical) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Allowance for Doubtful Accounts Receivable, Current	$ 30,000	$ 30,000
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	7,001,671	7,001,671
Common Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Common Stock, Shares Authorized	192,998,329	192,998,329
Common Stock, Shares, Issued	55,010,619	54,967,559
Common Stock, Shares, Outstanding	55,010,619	54,967,559
Treasury Stock, Shares	0	13,200
Series A Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series B Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	5,000,000	5,000,000
Preferred Stock, Shares Issued	59,065	59,065
Preferred Stock, Shares Outstanding	59,065	59,065
Series C Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,000,000	1,000,000
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0
Series D Preferred Stock [Member]
Preferred Stock, Par or Stated Value Per Share	$ 0.001	$ 0.001
Preferred Stock, Shares Authorized	1,671	1,671
Preferred Stock, Shares Issued	0	0
Preferred Stock, Shares Outstanding	0	0

Consolidated Statements of Oper

Consolidated Statements of Operations - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Product sales	$ 1,198,701	$ 1,158,109	$ 3,649,031	$ 3,265,795
Cost of product sales	1,132,397	1,102,912	3,472,357	3,303,364
Gross profit (loss)	66,304	55,197	176,674	(37,569)
Operating expenses:
Research and development	183,187	141,399	385,325	458,636
Sales and marketing	300,995	374,876	833,887	1,032,402
General and administrative	909,144	589,934	2,785,539	1,703,825
Total operating expenses	1,393,326	1,106,209	4,004,751	3,194,863
Operating loss	(1,327,022)	(1,051,012)	(3,828,077)	(3,232,432)
Non-operating income (expense):
Interest income	53,725	68,954	167,032	214,009
Change in fair value of warrant derivative liability	78,000	28,605	136,000	375,605
Financing and interest expense	0	(100)	(950)	(3,551)
Non-operating income (expense), net	131,725	97,459	302,082	586,063
Net loss	(1,195,297)	(953,553)	(3,525,995)	(2,646,369)
Preferred stock dividends	(2,658)	(2,658)	(7,974)	(7,974)
Net loss applicable to common shareholders	$ (1,197,955)	$ (956,211)	$ (3,533,969)	$ (2,654,343)
Basic and diluted loss per share (in dollars per share)	$ (0.02)	$ (0.02)	$ (0.06)	$ (0.05)
Weighted average shares used in computing net loss per share:
Basic and diluted (in shares)	55,022,668	54,883,551	55,010,619	54,878,297

Consolidated Statements of Cash

Consolidated Statements of Cash Flows - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
CASH FLOWS FROM OPERATING ACTIVITIES:
Net loss	$ (3,525,995)	$ (2,646,369)
Adjustments to reconcile net loss to net cash used by operating activities:
Allowance for doubtful accounts	0	(8,607)
Depreciation expense	412,170	439,223
Loss on equipment disposals	6,512	0
Writeoff of inventory associated with discontinued product	72,200	0
Amortization of other assets	25,494	34,923
Change in fair value of derivative warrant liability	(136,000)	(375,605)
Accretion of asset retirement obligation	65,933	60,278
Share-based compensation	229,442	64,360
Changes in operating assets and liabilities:
Accounts receivable, gross	165,339	(116,817)
Inventory	(125,536)	(104,818)
Other receivables	14,517	43,154
Prepaid expenses and other current assets	111	(9,171)
Accounts payable and accrued expenses	233,765	(135,198)
Accrued protocol expense	(26,452)	38,031
Accrued radioactive waste disposal	35,044	(23,469)
Accrued payroll and related taxes	(93,630)	(146,746)
Accrued vacation	(28,641)	(5,633)
Net cash used by operating activities	(2,675,727)	(2,892,464)
CASH FLOWS FROM INVESTING ACTIVITIES:
Payments for property and equipment	(259,517)	(77,963)
Additions to licenses and other assets	(2,992)	(14,016)
Proceeds from maturity of certificates of deposit	9,558,812	10,031,758
Purchases of certificates of deposit	(6,106,994)	(9,110,673)
Purchases of certificates of deposit, non-current	(85,185)	(4,744,580)
Change in restricted cash	(106)	(40)
Net cash provided (used) by investing activities	3,104,018	(3,915,514)
CASH FLOWS FROM FINANCING ACTIVITIES:
Preferred dividends paid	(10,632)	(10,632)
Proceeds from sales of common stock, pursuant to exercise of warrants, net	0	70,789
Proceeds from sales of common stock, pursuant to exercise of options	49,940	145,274
Net cash provided by financing activities	39,308	205,431
Net increase (decrease) in cash and cash equivalents	467,599	(6,602,547)
Cash and cash equivalents, beginning of period	5,226,740	7,680,073
CASH AND CASH EQUIVALENTS, END OF PERIOD	5,694,339	1,077,526
Non-cash investing and financing activities:
Retirement of treasury stock	8,390	0
Reclassification of derivative warrant liability to equity upon exercise	$ 0	$ 17,395

Basis of Presentation

Basis of Presentation	9 Months Ended
	Mar. 31, 2016
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Organization, Consolidation and Presentation of Financial Statements Disclosure and Significant Accounting Policies [Text Block]	1. Basis of Presentation The accompanying unaudited interim consolidated financial statements are those of IsoRay, Inc., and its wholly-owned subsidiaries (“IsoRay” or the “Company”). All significant intercompany accounts and transactions have been eliminated in the consolidation. In the opinion of management, all adjustments necessary for the fair presentation of the consolidated financial statements have been included. These unaudited interim consolidated financial statements should be read in conjunction with our audited consolidated financial statements and related footnotes as set forth in the Company’s annual report filed on Form 10-K for the year ended June 30, 2015. The unaudited consolidated financial statements have been prepared pursuant to the rules and regulations of the Securities and Exchange Commission. Certain information and footnote disclosures normally included in financial statements prepared in accordance with generally accepted accounting principles in the United States (GAAP) have been condensed or omitted pursuant to those rules and regulations, although we believe that the disclosures are adequate for the information not to be misleading. Certain prior period amounts have been reclassified to conform to the current period’s presentation. The results of operations for the periods presented may not be indicative of those which may be expected for a full year. The Company anticipates that as the result of continuing operating losses and the significant net operating losses available from prior fiscal years, its effective income tax rate for fiscal year 2016 will be 0

New Accounting Pronouncements

New Accounting Pronouncements	9 Months Ended
	Mar. 31, 2016
New Accounting Pronouncements and Changes in Accounting Principles [Abstract]
Description of New Accounting Pronouncements Not yet Adopted [Text Block]	2. New Accounting Pronouncements In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, Revenue Recognition. The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11 – Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01 – Financial Instruments – Overall. The guidance requires an entity’s management to measure equity investments except those accounted for under the equity method of accounting or those that result in consolidation of the investee to be measured at fair value; simplifies the impairment assessment of equity investments; eliminates the requirement to disclose the fair value of financial instruments measured at amortized cost for non-public entities: eliminates the requirement for a public entity to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is not permitted except as contained in the early adoption guidance. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

Certificates of deposit

Certificates of deposit	9 Months Ended
	Mar. 31, 2016
Investments, All Other Investments [Abstract]
Cost-method Investments, Description [Text Block]	3. Certificates of deposit The Company has maintained all excess cash in certificates of deposit at certain banks in certificates of deposit and through the Certificate of Deposit Account Registry Service (CDARS), which is a system that allows the Company to invest in certificates of deposit through a single financial institution that exceed the $ 250,000 As of March 31, 2016 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 5,910,756 $ - $ - $ 5,191,960 As of June 30, 2015 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 3,523,167 $ 500,064 $ 5,339,343 $ 5,106,775

Loss per Share

Loss per Share	9 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Earnings Per Share [Text Block]	4. Loss per Share Basic and diluted earnings per share are calculated by dividing net income (loss) available to common shareholders by the weighted average number of common shares outstanding, and does not include the impact of any potentially dilutive common stock equivalents. At March 31, 2016 and 2015, the calculation of diluted weighted average shares did not include convertible preferred stock, common stock warrants, or options that are potentially convertible into common stock as those would be antidilutive due to the Company’s net loss position. March 31, 2016 2015 Series B preferred stock 59,065 59,065 Common stock warrants 360,800 396,174 Common stock options 2,355,060 2,057,620 Total potential dilutive securities 2,774,925 2,512,859

Inventory

Inventory	9 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Inventory Disclosure [Text Block]	5. Inventory March 31, June 30, 2016 2015 Raw materials $ 223,588 $ 143,669 Work in process 225,978 204,760 Finished goods 7,725 55,526 $ 457,291 $ 403,955 March 31, June 30, 2016 2015 Enriched barium, non-current $ 469,758 $ 469,758 Raw materials, non-current 74,605 100,096 Total inventory, non-current $ 544,363 $ 569,854 Inventory, non-current is (i) raw materials that were ordered in quantities to obtain volume cost discounts for key components of our brachytherapy seed including titanium lids, titanium tubes, gold wires that are used for imaging markers, and our proprietary seed core, which were ordered based on current and anticipated sales volumes and will not be consumed within an operating cycle; and (ii) enriched barium, which is classified as non-current, and is only expected to be utilized if required to obtain volumes of isotope that is not able to be purchased from an existing source in either the short- or long-term. Management does not anticipate the need to utilize the enriched barium within the current operating cycle unless there is an unanticipated interruption to the isotope supply that requires its use. If such a need were to occur, then management would evaluate the need to reclassify some or all of the inventory as a current asset. As of March 31, 2016, the Company discontinued the GliaSite ® ® 72,200

Property and Equipment

Property and Equipment	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment Disclosure [Text Block]	6. Property and Equipment March 31, June 30, 2016 2015 Land $ 168,459 $ - Equipment 3,560,891 3,553,774 Leasehold improvements 4,129,977 4,129,977 Other 38,793 5,925 Property and equipment 7,898,120 7,689,676 Less accumulated depreciation (7,482,445) (7,114,836) Property and equipment , net $ 415,675 $ 574,840

Share-Based Compensation

Share-Based Compensation	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Disclosure of Compensation Related Costs, Share-based Payments [Text Block]	7. Share-Based Compensation Three months Nine months ended March 31, ended March 31, 2016 2015 2016 2015 Cost of product sales $ 17,757 $ 7,972 $ 52,947 $ 23,917 Research and development expenses 3,567 3,117 10,699 9,352 Sales and marketing expenses 3,744 2,158 10,230 6,475 General and administrative expenses 140,998 8,205 155,556 24,616 Total share-based compensation $ 166,066 $ 21,452 $ 229,442 $ 64,360 As of March 31, 2016, total unrecognized compensation expense related to stock-based options was $ 337,350 1.34 Weighted Weighted Exercise Average Number of Price Contractual Intrinsic Options (Years) Term Value Outstanding at March 31, 2016 2,380,060 $ 1.48 5.71 $ 289,393 Vested and expected to vest at March 31, 2016 2,294,065 $ 1.48 5.66 $ 282,800 Vested and exercisable at March 31, 2016 1,966,762 $ 1.46 5.01 $ 274,200 There were 56,260 133,564 27,469 145,275 There were 482,500 482,500 20,000 462,500 For the nine months ended Options issued 482,500 Weighted average exercise price $0.64 to $1.53 Expected term (in years) 1 to 5 Risk free rate 0.51% to 1.51% Weighted average volatility 106.21% to 108.26% There were 442,854 39,002 There were 21,608 84,236

Commitments and Contingencies

Commitments and Contingencies	9 Months Ended
	Mar. 31, 2016
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies Disclosure [Text Block]	8. Commitments and Contingencies Patent and Know-How Royalty License Agreement The Company is the holder of an exclusive license to use certain “know-how” developed by one of the founders of a predecessor to the Company and licensed to the Company by the Lawrence Family Trust, a Company shareholder. The terms of this license agreement require the payment of a royalty based on the Net Factory Sales Price, as defined in the agreement, of licensed product sales. Because the licensor’s patent application was ultimately abandoned, only a 1 The licensor of the “know-how” has disputed management’s contention that it is not using this “know-how”. On September 25, 2007 and again on October 31, 2007, the Company participated in nonbinding mediation regarding this matter; however, no settlement was reached with the Lawrence Family Trust. After additional settlement discussions, which ended in April 2008, the parties failed to reach a settlement. The parties may demand binding arbitration at any time. Class Action Lawsuit Related to Press Release On May 22, 2015, the first of three lawsuits was filed against IsoRay, Inc. and two of its officers – Dwight Babcock (the Company’s retired CEO) and Brien Ragle – related to a press release on May 20, 2015 regarding a May 19 online publication of the peer-reviewed article in the journal Brachytherapy On October 16, 2015, an amended complaint was filed with more detailed allegations relating to violations of federal securities laws and requesting damages through a jury trial. Mr. Ragle was dismissed from the complaint. On December 15, 2015, IsoRay filed a motion to dismiss the complaint altogether. Oral argument was scheduled on this motion on April 2016 but was rescheduled at the request of the plaintiff’s attorney to May 12, 2016. On April 1, 2016, IsoRay filed a reply in Support of Motion to Dismiss Amended Complaint for Violations of the Federal Securities Laws. IsoRay believes the lawsuit is without merit and is seeking its dismissal. Property Transaction between Medical and The Port of Benton On September 10, 2015, the Company’s operating subsidiary, Medical, entered into a Real Estate Purchase and Sale Agreement with The Port of Benton (“Port”), a municipal corporation of the State of Washington. The Agreement is for the sale of undeveloped real property of approximately 4.2 Medical is bound to comply with a Development Plan for a ten year period, the requirements of which include but are not limited to: (1) Certain specified site configurations and design with a minimum of 12,000 4,000 (2) Completion of all construction in two years; (3) Use of facility as primary production facility for ten (10) years; and (4) Provision of jobs for not less than 25 The purchase price for the property was adjusted in consideration of the Development Plan’s covenants. Failure to comply with these covenants will result in a breach of the Agreement and if not cured, will obligate Medical to pay the Port the difference in the sales price and the appraised value of the property at the time of default. The Benton County 2015 assessed value of the land was $ 423,720 256,000

Fair Value Measurements

Fair Value Measurements	9 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Fair Value Disclosures [Text Block]	9. Fair Value Measurements Fair value at March 31, 2016 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,694,339 $ 5,694,339 $ - $ - Warrant derivative liability 45,000 - 45,000 - Fair value at June 30, 2015 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,226,740 $ 5,226,740 $ - $ - Warrant derivative liability 181,000 - 181,000 -

Preferred Dividends

Preferred Dividends	9 Months Ended
	Mar. 31, 2016
Preferred Stock Dividends and Other Adjustments [Abstract]
Preferred Stock [Text Block]	10. Preferred Dividends On December 10, 2015, the Board of Directors declared a dividend on the Series B Preferred Stock of all currently payable and accrued outstanding and cumulative dividends through December 31, 2015 in the amount of $ 10,632 10,632

Shareholders' Equity

Shareholders' Equity	9 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Stockholders' Equity Note Disclosure [Text Block]	11. Shareholders’ Equity Warrant derivative liability Based on the guidance contained in ASC 815 “Derivatives and Hedging”, management has concluded that the warrants issued in the 2011 offering should be classified as a derivative liability and has recorded a liability at fair value. Quantity 1 Amount Balance at June 30, 2014 238,696 $ 573,000 Change in fair value - (374,605) Warrants exercised (13,209) (17,395) Balance at June 30, 2015 225,087 $ 181,000 Change in fair value - (15,000) Balance at September 30, 2015 225,087 166,000 Change in fair value - (43,000) Balance at December 31, 2015 225,087 123,000 Change in fair value - (78,000) Balance at March 31, 2016 225,087 $ 45,000 1 Quantity of warrants either issued or outstanding as of the date of valuation. Warrants Weighted average Warrants exercise price Outstanding as of June 30, 2015 385,800 $ 1.22 Warrants expired (25,000) 2.00 Outstanding as of March 31, 2016 360,800 $ 1.17 Number of Warrants Exercise Prices Expiration Date 130,713 $ 1.56 May 2016 199,437 0.94 October 2016 25,650 0.94 December 2016 5,000 0.98 June 2017 360,800

Related Party Transaction

Related Party Transaction	9 Months Ended
	Mar. 31, 2016
Related Party Transactions [Abstract]
Related Party Transactions Disclosure [Text Block]	12. Related Party Transaction During the nine months ended March 31, 2016 and 2015, the Company continued to engage the services of APEX Data Systems, Inc., owned by Dwight Babcock, the Company’s former Chairman and Chief Executive Officer, to modify and maintain the Company’s web interfaced data collection application to aggregate patient data in a controlled environment. The cost recorded during the nine months ended March 31, 2016 and 2015 from APEX Data Systems, Inc. for the maintenance of the web interfaced data collection applications in combination with the updating of the Company website was $ 6,000 6,000 6,000 2,000

Concentrations of Credit and Ot

Concentrations of Credit and Other Risks	9 Months Ended
	Mar. 31, 2016
Risks and Uncertainties [Abstract]
Concentration Risk Disclosure [Text Block]	13. Concentrations of Credit and Other Risks The Company’s cash, cash equivalents, and investments are deposited with several financial institutions with FDIC coverage. At times, deposits for a limited period of time in these institutions may exceed the amount of insurance provided on such deposits. The Company has not experienced any losses in such accounts and believes that it is not exposed to any significant risk on these balances. For the nine months ended March 31, 2016 and 2015, there was a single customer (which was a group of customers supported by a single physician group) that represented between 5 10 At March 31, 2016, one customer accounted for 10% or more of the Company’s total accounts receivable with that customer (a group of seven legal entities) representing 22 27 Accounts receivable are typically not collateralized. The Company maintains ongoing dialogue with its customers about invoice payments. Some of our customers are small outpatient surgery centers that pay invoices for our products at the time they receive a decision regarding payment by the insurer providing benefits which in the case of prostate cancer is predominately Medicare. A qualitative review of outstanding customer balances is performed at least quarterly and the allowance for doubtful accounts is adjusted based on historical performance of the customer and management knowledge regarding specific invoices. Accounts are charged against the allowance for doubtful accounts once collection efforts are deemed unsuccessful. Prior to utilizing an external collection agency and interrupting the supply of our product, customers may be provided the opportunity to continue purchasing product on the basis of pre-paying via guaranteed funds the amount due on their current order prior to producing and shipping the order plus the amount due on their oldest outstanding invoice. Single source suppliers presently provide the Company with several components. Management believes it would be able to locate other sources for these components subject to any regulatory qualifications if required. During the three months ended December 31, 2015, the Company experienced an unplanned supply disruption of radioisotope from its Russian supplier. No customer orders were missed or delayed while the Company increased production at its second supplier to compensate for the unplanned outage. This event has led management to conduct a review of the Company’s current supply interruption plan in such a situation to ensure its ability to continue to produce a sufficient supply of radioisotope at either facility in the case of an extended supply interruption at either reactor. Over the next nine to twelve months, management intends to vet, test and modify where appropriate the Company’s current plan as required to ensure this capability.

New Accounting Pronouncements (

New Accounting Pronouncements (Policies)	9 Months Ended
	Mar. 31, 2016
Accounting Policies [Abstract]
New Accounting Pronouncements, Policy [Policy Text Block]	In May 2014, the Financial Accounting Standards Board (FASB) issued Accounting Standards Update (ASU) 2014-09, Revenue from Contracts with Customers (ASU 2014-09), which supersedes the revenue recognition requirements in FASB Accounting Standards Codification (ASC) Topic 605, Revenue Recognition. The guidance requires that an entity recognize revenue in a way that depicts the transfer of promised goods or services to customers in the amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods and services. The guidance will be effective for annual reporting periods beginning after December 15, 2017, including interim periods within that reporting period, and is to be applied retrospectively, with early application not permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements. In July 2015, the FASB issued ASU No. 2015-11 – Inventory. The guidance requires an entity’s management to measure inventory within the scope of this ASU at the lower of cost and net realizable value. Net realizable value is the estimated selling prices in the ordinary course of business, less reasonably predictable costs of completion, disposal, and transportation. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2016. Early application is permitted. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements. In January 2016, the FASB issued ASU No. 2016-01 – Financial Instruments – Overall. The guidance requires an entity’s management to measure equity investments except those accounted for under the equity method of accounting or those that result in consolidation of the investee to be measured at fair value; simplifies the impairment assessment of equity investments; eliminates the requirement to disclose the fair value of financial instruments measured at amortized cost for non-public entities: eliminates the requirement for a public entity to disclose the method(s) and significant assumptions used to estimate the fair value that is required to be disclosed for financial instruments measured at amortized cost on the balance sheet; requires public business entities to use the exit price notion when measuring the fair value of financial instruments for disclosure purposes; requires an entity to present separately in other comprehensive income the portion of the total change in the fair value of a liability resulting from a change in the instrument-specific credit risk when the entity has elected to measure the liability at fair value in accordance with the fair value option for financial instruments; requires separate presentation of financial assets and financial liabilities by measurement category and form of financial asset (that is, securities or loans and receivables) on the balance sheet or the accompanying notes to the financial statements; and clarifies that an entity should evaluate the need for a valuation allowance on a deferred tax asset related to available-for-sale securities in combination with the entity’s other deferred tax assets. The guidance is effective for public business entities for fiscal years, and interim periods within those fiscal years, beginning after December 15, 2017. Early application is not permitted except as contained in the early adoption guidance. The Company is currently evaluating the new standard and its impact on the Company's consolidated financial statements.

Certificates of deposit (Tables

Certificates of deposit (Tables)	9 Months Ended
	Mar. 31, 2016
Investments, All Other Investments [Abstract]
Schedule of Cost Method Investments [Table Text Block]	As of March 31, 2016 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 5,910,756 $ - $ - $ 5,191,960 As of June 30, 2015 Under 90 91 days to Six months to Greater Days six months 1 year than 1 year CDARS $ 3,523,167 $ 500,064 $ 5,339,343 $ 5,106,775

Loss per Share (Tables)

Loss per Share (Tables)	9 Months Ended
	Mar. 31, 2016
Earnings Per Share [Abstract]
Schedule of Antidilutive Securities Excluded from Computation of Earnings Per Share [Table Text Block]	Securities not considered in the calculation of diluted weighted average shares, but that could be dilutive in the future as of March 31, 2016 and 2015, were as follows: March 31, 2016 2015 Series B preferred stock 59,065 59,065 Common stock warrants 360,800 396,174 Common stock options 2,355,060 2,057,620 Total potential dilutive securities 2,774,925 2,512,859

Inventory (Tables)

Inventory (Tables)	9 Months Ended
	Mar. 31, 2016
Inventory Disclosure [Abstract]
Schedule of Inventory, Current [Table Text Block]	Inventory consisted of the following at March 31, 2016 and June 30, 2015: March 31, June 30, 2016 2015 Raw materials $ 223,588 $ 143,669 Work in process 225,978 204,760 Finished goods 7,725 55,526 $ 457,291 $ 403,955
Schedule of Inventory, Noncurrent [Table Text Block]	March 31, June 30, 2016 2015 Enriched barium, non-current $ 469,758 $ 469,758 Raw materials, non-current 74,605 100,096 Total inventory, non-current $ 544,363 $ 569,854

Property and Equipment (Tables)

Property and Equipment (Tables)	9 Months Ended
	Mar. 31, 2016
Property, Plant and Equipment [Abstract]
Property, Plant and Equipment [Table Text Block]	March 31, June 30, 2016 2015 Land $ 168,459 $ - Equipment 3,560,891 3,553,774 Leasehold improvements 4,129,977 4,129,977 Other 38,793 5,925 Property and equipment 7,898,120 7,689,676 Less accumulated depreciation (7,482,445) (7,114,836) Property and equipment , net $ 415,675 $ 574,840

Share-Based Compensation (Table

Share-Based Compensation (Tables)	9 Months Ended
	Mar. 31, 2016
Disclosure of Compensation Related Costs, Share-based Payments [Abstract]
Schedule of Employee Service Share-based Compensation, Allocation of Recognized Period Costs [Table Text Block]	The following table presents the share-based compensation expense recognized during the three months and nine months ended March 31, 2016 and 2015: Three months Nine months ended March 31, ended March 31, 2016 2015 2016 2015 Cost of product sales $ 17,757 $ 7,972 $ 52,947 $ 23,917 Research and development expenses 3,567 3,117 10,699 9,352 Sales and marketing expenses 3,744 2,158 10,230 6,475 General and administrative expenses 140,998 8,205 155,556 24,616 Total share-based compensation $ 166,066 $ 21,452 $ 229,442 $ 64,360
Schedule of Share-based Compensation Arrangement by Share-based Payment Award, Options, Vested and Expected to Vest, Outstanding [Table Text Block]	A summary of stock options within the Company’s share-based compensation plans as of March 31, 2016 was as follows: Weighted Weighted Exercise Average Number of Price Contractual Intrinsic Options (Years) Term Value Outstanding at March 31, 2016 2,380,060 $ 1.48 5.71 $ 289,393 Vested and expected to vest at March 31, 2016 2,294,065 $ 1.48 5.66 $ 282,800 Vested and exercisable at March 31, 2016 1,966,762 $ 1.46 5.01 $ 274,200
Schedule of Share-based Payment Award, Stock Options, Valuation Assumptions [Table Text Block]	For the nine months ended Options issued 482,500 Weighted average exercise price $0.64 to $1.53 Expected term (in years) 1 to 5 Risk free rate 0.51% to 1.51% Weighted average volatility 106.21% to 108.26%

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	9 Months Ended
	Mar. 31, 2016
Fair Value Disclosures [Abstract]
Schedule of Fair Value, Assets and Liabilities Measured on Recurring Basis [Table Text Block]	The table below sets forth the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of March 31, 2016 and June 30, 2015, respectively, and the fair value calculation input hierarchy level the Company has determined applies to each asset and liability category. Fair value at March 31, 2016 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,694,339 $ 5,694,339 $ - $ - Warrant derivative liability 45,000 - 45,000 - Fair value at June 30, 2015 Total Level 1 Level 2 Level 3 Cash and cash equivalents $ 5,226,740 $ 5,226,740 $ - $ - Warrant derivative liability 181,000 - 181,000 -

Shareholders' Equity (Tables)

Shareholders' Equity (Tables)	9 Months Ended
	Mar. 31, 2016
Stockholders' Equity Note [Abstract]
Fair Value, Assets and Liabilities Measured on Nonrecurring Basis, Valuation Techniques [Table Text Block]	A summary of the change in fair value of derivative warrant liability is as follows for the fiscal years presented. Quantity 1 Amount Balance at June 30, 2014 238,696 $ 573,000 Change in fair value - (374,605) Warrants exercised (13,209) (17,395) Balance at June 30, 2015 225,087 $ 181,000 Change in fair value - (15,000) Balance at September 30, 2015 225,087 166,000 Change in fair value - (43,000) Balance at December 31, 2015 225,087 123,000 Change in fair value - (78,000) Balance at March 31, 2016 225,087 $ 45,000 1 Quantity of warrants either issued or outstanding as of the date of valuation.
Schedule of Stockholders Equity Note Warrants or Rights [Table Text Block]	The following table summarizes all warrants outstanding as of the beginning of the fiscal year, all activity related to warrants issued, cancelled, exercised or expired during the period and weighted average prices by category. Weighted average Warrants exercise price Outstanding as of June 30, 2015 385,800 $ 1.22 Warrants expired (25,000) 2.00 Outstanding as of March 31, 2016 360,800 $ 1.17
Schedule Of Stockholders Equity Note Warrants Or Rights By Exercise Price Range [Table Text Block]	The following table summarizes additional information about the Company’s common warrants outstanding as of March 31, 2016: Number of Warrants Exercise Prices Expiration Date 130,713 $ 1.56 May 2016 199,437 0.94 October 2016 25,650 0.94 December 2016 5,000 0.98 June 2017 360,800

Basis of Presentation (Details

Basis of Presentation (Details Textual)	12 Months Ended
	Jun. 30, 2016
Scenario, Forecast [Member]
Basis Of Presentation [Line Items]
Effective Income Tax Rate Reconciliation, Percent, Total	0.00%

Certificates of deposit (Detail

Certificates of deposit (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Under 90 Days [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	$ 5,910,756	$ 3,523,167
91 Days to Six Months [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	0	500,064
Six Months to 1 Year [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	0	5,339,343
Greater than 1 Year [Member]
Schedule of Cost-method Investments [Line Items]
Investment Owned, at Cost	$ 5,191,960	$ 5,106,775

Certificates of deposit (Deta29

Certificates of deposit (Details Textual)	9 Months Ended
	Mar. 31, 2016USD ($)
Certificates of deposit [Line Items]
Federal Deposit Insurance Corporation Limits On Deposits In Financial Institutions	$ 250,000

Loss per Share (Details)

Loss per Share (Details) - shares	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,774,925	2,512,859
Series B Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	59,065	59,065
Common stock warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	360,800	396,174
Common stock options [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Antidilutive Securities Excluded from Computation of Earnings Per Share, Amount	2,355,060	2,057,620

Inventory (Details)

Inventory (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Inventory [Line Items]
Raw materials	$ 223,588	$ 143,669
Work in process	225,978	204,760
Finished goods	7,725	55,526
Inventory, Net, Total	457,291	403,955
Total inventory, non-current	544,363	569,854
Enriched Barium Inventory [Member]
Inventory [Line Items]
Total inventory, non-current	469,758	469,758
Raw Materials [Member]
Inventory [Line Items]
Total inventory, non-current	$ 74,605	$ 100,096

Inventory (Details Textual)

Inventory (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Inventory Write-down	$ 72,200	$ 0
GliaSite® RTS [Member]
Inventory Write-down	$ 72,200

Property and Equipment (Details

Property and Equipment (Details) - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Property, Plant and Equipment [Line Items]
Property and equipment	$ 7,898,120	$ 7,689,676
Less accumulated depreciation	(7,482,445)	(7,114,836)
Property and equipment , net	415,675	574,840
Leasehold Improvements [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	4,129,977	4,129,977
Other [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	38,793	5,925
Land [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	168,459	0
Equipment [Member]
Property, Plant and Equipment [Line Items]
Property and equipment	$ 3,560,891	$ 3,553,774

Share-Based Compensation (Detai

Share-Based Compensation (Details) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	$ 166,066	$ 21,452	$ 229,442	$ 64,360
Cost of product sales [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	17,757	7,972	52,947	23,917
Research and Development Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	3,567	3,117	10,699	9,352
Selling and Marketing Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	3,744	2,158	10,230	6,475
General and Administrative Expense [Member]
Share-based Compensation Arrangement by Share-based Payment Award, Compensation Cost [Line Items]
Total share-based compensation	$ 140,998	$ 8,205	$ 155,556	$ 24,616

Share-Based Compensation (Det35

Share-Based Compensation (Details 1)	9 Months Ended
	Mar. 31, 2016USD ($)$ / sharesshares
Number of Options
Outstanding at March 31, 2016 | shares	2,380,060
Vested and expected to vest at March 31, 2016 | shares	2,294,065
Vested and exercisable at March 31, 2016 | shares	1,966,762
Weighted Exercise Price
Outstanding at March 31, 2016 | $ / shares	$ 1.48
Vested and expected to vest at March 31, 2016 | $ / shares	1.48
Vested and exercisable at March 31, 2016 | $ / shares	$ 1.46
Weighted Average Contractual Term
Outstanding at March 31, 2016	5 years 8 months 16 days
Vested and expected to vest at March 31, 2016	5 years 7 months 28 days
Vested and exercisable at March 31, 2016	5 years 4 days
Intrinsic Value
Outstanding at March 31, 2016 | $	$ 289,393
Vested and expected to vest at March 31, 2016 | $	282,800
Vested and exercisable at March 31, 2016 | $	$ 274,200

Share-Based Compensation (Det36

Share-Based Compensation (Details 2) - $ / shares	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Options issued	482,500	0
Risk free rate, Minimum	0.51%
Risk free rate, Maximum	1.51%
Minimum [Member]
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Weighted average exercise price	$ 0.64
Expected term (in years)	1 year
Weighted average volatility	106.21%
Maximum [Member]
Share Based Payment Award Stock Options Valuation Assumptions [Line Items]
Weighted average exercise price	$ 1.53
Expected term (in years)	5 years
Weighted average volatility	108.26%

Share-Based Compensation (Det37

Share-Based Compensation (Details Textual) - USD ($)	3 Months Ended		9 Months Ended
	Mar. 31, 2016	Sep. 30, 2015	Mar. 31, 2016	Mar. 31, 2015
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Total	$ 337,350		$ 337,350
Employee Service Share-based Compensation, Nonvested Awards, Compensation Cost Not yet Recognized, Period for Recognition			1 year 4 months 2 days
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period			56,260	133,564
Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period, Intrinsic Value			$ 27,469	$ 145,275
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			482,500	0
Share-based Compensation Arrangement by Share-based Payment Award, Shares Issued in Period	462,500	20,000
Employee Stock Option [Member]
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Gross			482,500
Share-based Compensation Arrangement by Share-based Payment Award, Options, Expirations in Period			442,854	39,002
Share-based Compensation Arrangement by Share-based Payment Award, Options, Forfeitures in Period			21,608	84,236

Commitments and Contingencies (

Commitments and Contingencies (Details Textual)	9 Months Ended
	Mar. 31, 2016USD ($)a	Mar. 31, 2015USD ($)
Unrecorded Unconditional Purchase Obligation [Line Items]
Area of Land | a	4.2
Number Of Employees Commitment	25
Percentage Of Royalty Rate Payable	1.00%
Gain (Loss) on Disposition of Property Plant Equipment, Total | $	$ (6,512)	$ 0
The Benton Country 2015 [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Land | $	423,720
Gain (Loss) on Disposition of Property Plant Equipment, Total | $	$ 256,000
Capital Addition Purchase Commitments [Member] | Warehouse Space [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Area of Real Estate Property | a	12,000
Capital Addition Purchase Commitments [Member] | Office Space [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Area of Land | a	4,000
Primary Use Agreement [Member]
Unrecorded Unconditional Purchase Obligation [Line Items]
Term of Unrecorded Unconditional Purchase Obligation	10 Years

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Fair Value, Measurements, Recurring [Member] - USD ($)	Mar. 31, 2016	Jun. 30, 2015
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	$ 5,694,339	$ 5,226,740
Warrant derivative liability	45,000	181,000
Fair Value, Inputs, Level 1 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	5,694,339	5,226,740
Warrant derivative liability	0	0
Fair Value, Inputs, Level 2 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Warrant derivative liability	45,000	181,000
Fair Value, Inputs, Level 3 [Member]
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis [Line Items]
Cash and cash equivalents	0	0
Warrant derivative liability	$ 0	$ 0

Preferred Dividends (Details Te

Preferred Dividends (Details Textual) - USD ($)	6 Months Ended		9 Months Ended
	Dec. 31, 2015	Dec. 31, 2014	Mar. 31, 2016	Mar. 31, 2015
Preferred dividends paid	$ 10,632	$ 10,632	$ 10,632	$ 10,632

Shareholders' Equity (Details)

Shareholders' Equity (Details) - USD ($)		3 Months Ended					9 Months Ended				12 Months Ended
		Mar. 31, 2016	Dec. 31, 2015	Sep. 30, 2015		Mar. 31, 2015	Mar. 31, 2016		Mar. 31, 2015		Jun. 30, 2015
Class of Warrant or Right [Line Items]
Balance				385,800			385,800
Balance		360,800					360,800				385,800
Value of warrants issued:
Change in fair value		$ (78,000)				$ (28,605)	$ (136,000)		$ (375,605)
Derivative Warrants [Member]
Class of Warrant or Right [Line Items]
Balance		225,087	225,087	225,087	[1]		225,087	[1]	238,696	[1]	238,696	[1]
Warrants exercised	[1]										(13,209)
Balance		225,087	225,087	225,087			225,087				225,087	[1]
Value of warrants issued:
Balance		$ 123,000	$ 166,000	$ 181,000			$ 181,000		$ 573,000		$ 573,000
Change in fair value		(78,000)	(43,000)	(15,000)							(374,605)
Warrants exercised											(17,395)
Balance		$ 45,000	$ 123,000	$ 166,000			$ 45,000				$ 181,000
[1]	Quantity of warrants either issued or outstanding as of the date of valuation.

Shareholders' Equity (Details 1

Shareholders' Equity (Details 1)	9 Months Ended
	Mar. 31, 2016$ / sharesshares
Warrants
Balance | shares	385,800
Warrants expired | shares	(25,000)
Balance | shares	360,800
Weighted average exercise price
Beginning balance outstanding | $ / shares	$ 1.22
Warrants expired | $ / shares	2
Ending balance outstanding | $ / shares	$ 1.17

Shareholders' Equity (Details 2

Shareholders' Equity (Details 2) - $ / shares	9 Months Ended
	Mar. 31, 2016	Jun. 30, 2015
Class of Warrant or Right [Line Items]
Number of Warrants	360,800	385,800
Range of Exercise Prices	$ 1.17	$ 1.22
Range of Exercise Price One [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	130,713
Range of Exercise Prices	$ 1.56
Expiration Date	May 2,016
Range of Exercise Price Two [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	199,437
Range of Exercise Prices	$ 0.94
Expiration Date	October 2,016
Range of Exercise Price Three [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	25,650
Range of Exercise Prices	$ 0.94
Expiration Date	December 2,016
Range of Exercise Price Four [Member]
Class of Warrant or Right [Line Items]
Number of Warrants	5,000
Range of Exercise Prices	$ 0.98
Expiration Date	June 2,017

Related Party Transaction (Deta

Related Party Transaction (Details Textual) - USD ($)	9 Months Ended
	Mar. 31, 2016	Mar. 31, 2015
Related Party Transaction [Line Items]
Maintenance costs	$ 6,000	$ 6,000
Software implementation costs	6,000	6,000
Due to Related Parties, Current	$ 2,000	$ 2,000

Concentrations of Credit and 45

Concentrations of Credit and Other Risks (Details Textual)	9 Months Ended		12 Months Ended
	Mar. 31, 2016	Mar. 31, 2015	Jun. 30, 2015
Accounts Receivable [Member] | Credit Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage	22.00%		27.00%
Sales Revenue, Net [Member] | Customer Concentration Risk [Member]
Product Information [Line Items]
Concentration Risk, Percentage	5.00%	10.00%